Amneal Pharmaceuticals, Inc. AMRX Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s total non-current liabilities?
- Amneal Pharmaceuticals, Inc. (AMRX) reported total non-current liabilities of $2.77B in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s total non-current liabilities changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s total non-current liabilities increased by 18.0% year-over-year, from $2.35B to $2.77B.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total non-current liabilities?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s total non-current liabilities has grown at a -1.3% compound annual growth rate (CAGR), from $2.97B to $2.79B.
- What does total non-current liabilities mean?
- The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.